Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · DaVita (DVA)

DaVita names David Maughan Chief Operating Officer, Kidney Care, effective September 15

Neutral Impact 3 of 5 leadership Written later

DaVita appointed Senior Vice President David P. Maughan as Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024, replacing Michael D. Staffieri, who moves to Chief Operating Officer Emeritus. The company also entered an employment agreement with Maughan with a $725,000 base salary and a 2024 target bonus of 100% of base salary.

Key points

  • David P. Maughan, 47, succeeds Michael D. Staffieri as COO, DaVita Kidney Care, effective September 15, 2024
  • Maughan joined DaVita in 2006 and most recently served as Senior Vice President, Kidney Care, from November 2019 to September 2024
  • Employment agreement sets annual base salary of $725,000 and a 2024 target incentive bonus equal to 100% of base salary
  • Severance includes at least one year of base salary continuation on resignation for good cause, or two years within 60 days after a good-cause event following a change in control

The filing

CompanyDaVita (DVA)
Form8-K, current report
Filed with the SECSep 13, 2024, 4:15 PM ET
Accession number0001206774-24-000897

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 13, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.